ReviewJournal of nanobiotechnology2026
Augmenting the catalytic activity of ADzymes: strategic engineering from atomic structure design to macro-environmental interaction for enhanced biomedical efficacy.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Nanozymes with atomically dispersed metal sites (ADzymes), characterized by well-defined active centers, high catalytic efficiency, and tunable catalytic properties, have expanded the horizons for developing bio-inspired solutions to address critical challenges in healthcare domains. Herein, this article systematically reviews the synthesis and characterization methods, and classification system of ADzymes, and summarizes the strategies to enhance their catalytic activity ranging from micro- to macro-scales. Key strategies discussed include the biomimetic design of metal active centers, modulation of coordination environments, support interface engineering, and external-field-responsive dynamic activation. Furthermore, the potential applications of ADzymes in ROS-mediated biomedical therapies are highlighted. Based on the systematic deconstruction of the structure-activity relationship, this review provides a theoretical foundation for the rational design of high-performance artificial enzymes. Finally, the current bottlenecks and future perspectives regarding the regulation of ADzymes for clinical translation are discussed, providing insights into their evolution from empirical screening to intelligent design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.